Latest Insider Transactions at Myriad Genetics Inc (MYGN)
This section provides a real-time view of insider transactions for Myriad Genetics Inc (MYGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MYRIAD GENETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MYRIAD GENETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 09
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,483
-3.6%
|
$374,490
$30.88 P/Share
|
Oct 09
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,811
-1.98%
|
$324,330
$30.88 P/Share
|
Oct 09
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,398
-1.69%
|
$371,940
$30.88 P/Share
|
Oct 09
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,340
-2.08%
|
$250,200
$30.88 P/Share
|
Oct 01
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,420
-0.8%
|
$44,020
$31.57 P/Share
|
Sep 27
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,112
-5.37%
|
$333,696
$33.1 P/Share
|
Sep 26
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,541
-1.22%
|
$149,853
$33.31 P/Share
|
Sep 26
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,216
-1.97%
|
$73,128
$33.31 P/Share
|
Sep 26
2021
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
865
-1.55%
|
$28,545
$33.31 P/Share
|
Sep 26
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,514
-1.71%
|
$115,962
$33.31 P/Share
|
Sep 26
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,426
-1.79%
|
$113,058
$33.31 P/Share
|
Sep 26
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,633
-1.3%
|
$119,889
$33.31 P/Share
|
Sep 25
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,907
-3.09%
|
$392,931
$33.31 P/Share
|
Sep 25
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,878
-3.34%
|
$127,974
$33.31 P/Share
|
Sep 25
2021
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
346
-0.62%
|
$11,418
$33.31 P/Share
|
Sep 25
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,746
-3.17%
|
$222,618
$33.31 P/Share
|
Sep 25
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,311
-0.68%
|
$43,263
$33.31 P/Share
|
Sep 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,747
-3.38%
|
$321,651
$33.31 P/Share
|
Sep 23
2021
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
49,390
-5.84%
|
$1,679,260
$34.76 P/Share
|
Sep 23
2021
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
445,439
+34.51%
|
-
|
Sep 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200
-0.07%
|
$7,000
$35.06 P/Share
|
Sep 21
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,977
+14.8%
|
-
|
Sep 21
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,398
+16.82%
|
-
|
Sep 21
2021
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,571
+11.82%
|
-
|
Sep 21
2021
|
Nicole Lambert Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,870
+25.45%
|
-
|
Sep 21
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,598
+18.62%
|
-
|
Sep 17
2021
|
Jayne B. Hart Officer |
SELL
Open market or private sale
|
Direct |
67,446
-22.63%
|
$2,225,718
$33.72 P/Share
|
Sep 17
2021
|
Jayne B. Hart Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,000
+18.12%
|
$2,002,000
$26.49 P/Share
|
Aug 27
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
945
-0.74%
|
$32,130
$34.5 P/Share
|
Aug 25
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,058
-0.95%
|
$103,972
$34.81 P/Share
|
Aug 25
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,233
-0.96%
|
$75,922
$34.81 P/Share
|
Aug 25
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,082
-0.69%
|
$36,788
$34.81 P/Share
|
Aug 25
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,123
-0.87%
|
$38,182
$34.81 P/Share
|
Aug 25
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,148
-1.41%
|
$39,032
$34.81 P/Share
|
Aug 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,000
-11.43%
|
$1,050,000
$35.57 P/Share
|
Aug 24
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+10.25%
|
$810,000
$27.07 P/Share
|
Aug 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.4%
|
$1,750,000
$35.32 P/Share
|
Aug 23
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.38%
|
$1,350,000
$27.07 P/Share
|
Aug 13
2021
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
58,820
-12.82%
|
$1,882,240
$32.79 P/Share
|
Aug 10
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
3,250
-1.0%
|
-
|
Aug 05
2021
|
S. Louise Phanstiel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+23.08%
|
$1,380,000
$23.34 P/Share
|
Aug 05
2021
|
S. Louise Phanstiel Director |
SELL
Open market or private sale
|
Direct |
47,881
-43.72%
|
$1,675,835
$35.04 P/Share
|
Aug 05
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
28,225
-10.82%
|
$987,875
$35.57 P/Share
|
Aug 05
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,225
+9.77%
|
$762,075
$27.07 P/Share
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-9.47%
|
$1,750,000
$35.41 P/Share
|
Aug 04
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.48%
|
$1,350,000
$27.07 P/Share
|
Aug 03
2021
|
Dennis Langer Director |
SELL
Open market or private sale
|
Direct |
30,000
-25.1%
|
$1,020,000
$34.75 P/Share
|
Aug 03
2021
|
Dennis Langer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+20.06%
|
$750,000
$25.39 P/Share
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-4.93%
|
$1,700,000
$34.27 P/Share
|
Aug 03
2021
|
Jerry S Lanchbury Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+4.57%
|
$1,250,000
$25.38 P/Share
|